Quantcast

Latest Boehringer Ingelheim Stories

2014-10-21 08:34:10

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Empagliflozin plus metformin is part of the Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) Diabetes alliance portfolio. "Type 2...

2014-10-21 08:33:34

-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment RIDGEFIELD, Conn., Oct. 21, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases...

2014-10-20 16:27:01

Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct. 20, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV® (nintedanib) capsules are now commercially available in the United States. OFEV was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). It is the only kinase inhibitor approved to treat...

2014-10-14 04:22:12

BONN, Germany, October 14, 2014 /PRNewswire/ -- Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising EUR9.45 million. The round was co-led by Wellington Partners and Boehringer Ingelheim Venture Fund, and included NRW Bank and High-Tech Gruenderfonds (HTGF). Rigontec is developing synthetic ligands of a novel...

2014-10-08 08:26:47

RIDGEFIELD, Conn., Oct. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. STRIVERDI RESPIMAT is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat asthma...

2014-10-08 04:21:11

Case Funding Company says recent $650MM settlement of approximately 4K filed cases in both state and federal courts over blood thinner, amounts to an average Pradaxa settlement amount or settlement value of approximately $150K per case. SAN FRANCISCO, Oct. 8, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that they are increasing their pre-settlement and settlement funding amounts on all Pradaxa cases based on the recent settlement by...

2014-09-30 23:24:17

As Pradaxa Lawsuit Claims Continue Boehringer Ingelheim Conducts Clinical Trials On Idarucizumab, A Potential Reversal Agent To Pradaxa Columbus, OH (PRWEB) September 30, 2014 Wright & Schulte LLC has learned that Boehringer Ingelheim Pharmaceuticals, Inc. is testing a possible antidote for Pradaxa, the company’s oral anticoagulant that is the focus of almost 2500 Pradaxa lawsuits pending in the U.S. District Court, Southern District of Illinois alleging uncontrollable bleeding. The...

2014-09-30 08:31:22

New Executive Brings Experience from Merck, Boehringer Ingelheim, and Proctor & Gamble PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into...

2014-09-26 12:25:01

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting today's public meeting to better understand the daily experiences of those living with idiopathic pulmonary fibrosis (IPF), a serious and life-threatening lung disease in which most patients live only three to five years after diagnosis. The patient and caregiver stories that will be shared with the FDA and the public today may help shed light on...

2014-09-25 08:27:29

Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva® Respimat® (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related